WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of construction on a new manufacturing site in Delaware, United States. The 190-acre campus in Middletown, first announced in June 2021, will serve as STA’s second facility in the US.
Key Details of the New Campus
Phase I of the new Delaware campus will offer a comprehensive range of services, including formulation development, clinical, and commercial drug product manufacturing for various oral and injectable dosage forms. Additionally, the site will provide packaging, labeling, storage, and distribution services for clinical trial materials and commercial drug products.
Global Presence and Expansion
WuXi STA currently operates 12 sites across the US, Europe, and Asia. The Delaware site will be the fourth globally to offer drug product manufacturing services, joining facilities in Couvet, Switzerland, and the cities of Wuxi and Shanghai in China. This expansion underscores WuXi STA’s commitment to enhancing its global manufacturing capabilities and supporting the biopharmaceutical industry’s growing needs.-Fineline Info & Tech
